Scarica l'app Stockscreener
21.95
1.81%
0.39
Pre-mercato:
21.51
-0.44
-2.00%
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? - AOL.com
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? - The Motley Fool
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan
Bicara Therapeutics (BCAX) director receives 19,475-share option tied to RA Capital - Stock Titan
[8-K] Bicara Therapeutics Inc. Reports Material Event - Stock Titan
Bicara Therapeutics Inc. presents three year Phase 1b results for ficerafusp alfa combination in HPV negative HNSCC - Traders Union
BCAX News | BICARA THERAPEUTICS INC (NASDAQ:BCAX) - ChartMill
BCAX Stock Price, Quote & Chart | BICARA THERAPEUTICS INC (NASDAQ:BCAX) - ChartMill
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Cantor Fitzgerald reiterates Bicara Therapeutics stock rating - Investing.com
Cantor Fitzgerald reiterates Bicara Therapeutics stock rating By Investing.com - Investing.com India
Bicara (BCAX) Q4 2025 Earnings Transcript - AOL.com
Analyst Reiterates Buy on Bicara, Keeps 12-Month Price Target Unchanged at $42 on Encouraging Ficerafusp Alfa Data - TipRanks
Bicara Therapeutics Inc. presents breakthrough in EGFR-targeted therapy for HPV-negative HNSCC - Traders Union
Bicara Therapeutics CFO Ivan Hyep sells $187,883 in stock By Investing.com - Investing.com India
Bicara Therapeutics CFO Ivan Hyep sells $187,883 in stock - Investing.com
BCAX (Nasdaq: BCAX) insider notice: 5,500 shares tied to option exercise - Stock Titan
Bicara Therapeutics Inc. launches FORTIFI clinical trial targeting 1L R/M HPV negative HNSCC patients - Traders Union
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
BCAX: Ficera doubled three-year survival and achieved deep, durable responses in HPV-negative head and neck cancer - TradingView
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer - TradingView
BCAX: Ficerafusp alfa delivers deep, durable responses and doubles three-year survival in HPV-negative head and neck cancer - TradingView
BCAX: FICERA plus pembrolizumab delivers deep, durable responses and extended survival in HPV-negative HNSCC - TradingView
Bicara Therapeutics Reports Positive Three-Year Survival Data for Ficerafusp Alfa Plus Pembrolizumab in 1L R/M HPV-Negative HNSCC - Minichart
Bicara reports three-year survival data for cancer therapy By Investing.com - Investing.com South Africa
Bicara reports three-year survival data for cancer therapy - Investing.com
Bicara Therapeutics Reports Promising Three-Year Follow-Up Data for Ficerafusp Alfa in Combination with Pembrolizumab in HPV-Negative Head and Neck Cancer - Quiver Quantitative
Bicara Therapeutics: 1500mg Ficerafusp Alfa + Pembrolizumab Shows Estimated 31% 3‑Year OS in 1L R/M HPV‑Negative HNSCC - TradingView
New data from Bicara Therapeutics Inc. reveals long term outcomes from HPV negative HNSCC trial - Traders Union
Ficerafusp Alfa Plus Pembrolizumab Demonstrated - GlobeNewswire
Bicara Therapeutics (BCAX) CEO sells 15K shares and exercises options - Stock Titan
Bicara Therapeutics Highlights Momentum in Earnings Call - TipRanks
A Look At Bicara Therapeutics (BCAX) Valuation After Recent Share Price Pullback - Yahoo Finance
Bicara Therapeutics’ Earnings Call Highlights Ficera Momentum - TipRanks
Bicara Therapeutics president & COO Ryan Cohlhepp sells $253k stock - Investing.com
Bicara Therapeutics president & COO Ryan Cohlhepp sells $253k stock By Investing.com - Investing.com South Africa
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):